|
|
|
|
 |
| February 23, 2012 | ISSUE NUMBER 239 VOL 8 |
|
Evidence
Betting on Real-World Data
AstraZeneca launched its real-world evidence collaboration with IMS Health with some fanfare earlier this year. But will it be successful in showing value?
...Read More
Europe
Servier at a Crossroads
The French pharma has a number of collaborations that could lead to a new generation of products, but any positive news is likely to be overshadowed by the safety scandal of its diabetes treatment Mediator. The case has already led to changes in the way that France approaches the regulation and promotion of medicines. Whatever emerges over the next year also has the potential to influence markets in other countries, which will be keen to safeguard against any flaws proven in the French system.
...Read More
Regulation
FDA Taking Steps Toward Quantitative Safety Assessment
In the past, FDA has used observation and statistical analysis to detect side effects during clinical development. But new technologies offer an increasingly sophisticated look at how a drug candidate, or combination of drugs, is processed by the human body. ...Read More
Sales
Fully Mobilizing Your Mobile Technology
The market is now awash with highly functional, lightweight tablets, which has enabled field users to maximize the short time available to them with HCPs. And with the long battery life and instant-on technology, the door is open for innovative ways of sharing information. ...Read more
 |
|
|
 // Astellas Pharma (Deerfield, IL) announced that Charlotte M.E. Kremer, MD, MBA, has joined the company as the Head of Global Medical Affairs.
// Tom Lyon was appointed Vice President and Site Head at Roche's Nutley, N.J., plant. // Dr. Marian Meyer has been named Director of Laboratories at OSO BioPharmaceuticals Manufacturing (Albuquerque, NM). // Integrated Diagnostics (Seattle) appointed Donald Seaton as Chief Financial Officer and James Garner as Chief Business Officer.// Patrick MacCarthy was named as the Vice President of Marketing at NinePoint Medical (Cambridge, MA).
|
|
|
 |
|
|
|
|
 |
|
 |
|
|
 |
|
 |
|
 |
 |
|
 |
What do you think the pharma marketing landscape of 2017 will look like?
|
|
|
|
|
You
are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To
ensure delivery to your Inbox, please add us to your
address book. If you need help doing this, click
here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
